Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Person › Details

Clive R. Wood (Boehringer Ingelheim (Group))

Wood, Clive R. (Boehringer 201403– SVP Discovery Research before Bayer HealthCare + Dyax)

	Organisation	Boehringer Ingelheim (Group)
	Former/major organisation	Bayer HealthCare (Group)
	Group	Bayer (Group)
	Product	drug discovery
	Product 2	biopharmaceutical

Record changed: 2024-10-10

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Clive R. Wood

[1] Boehringer Ingelheim. (10/9/24). "Press Release: Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment". Ingelheim & South San Francisco, CA....
[2] Boehringer Ingelheim. (5/22/24). "Press Release: Boehringer Ingelheim and OSE Immunotherapeutics Expand Collaboration to Develop First-in-class Treatments for Cancer and Cardio-renal-metabolic Diseases". Ingelheim & Nantes....
[3] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim to Start Phase 1 Development of BI 771716 – a Potential New Treatment for Geographic Atrophy, a Leading Cause of Blindness Worldwide". Ingelheim & Basel....
[4] Boehringer Ingelheim. (10/19/21). "Press Release: Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis". Paris....
[5] Twist Bioscience Corporation. (9/9/21). "Press Release: Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration". South San Francisco, CA & Ingelheim....
[6] Boehringer Ingelheim. (1/9/20). "Press Release: Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases". Ingelheim & Singapore....
[7] Boehringer Ingelheim. (10/29/19). "Press Release: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing". Ingelheim....
[8] Boehringer Ingelheim. (9/20/19). "Press Release: Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases". Ingelheim & Newton, MA....
[9] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
[10] PureTech Health plc. (4/17/19). "Press Release: PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates Using Its Lymphatic Targeting Platform". Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

» top